Sanofi/Regeneron
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 7 disclosed transactions, Sanofi/Regeneron concentrates its licensing activity in Immunology, Oncology, and Gastroenterology. Sanofi/Regeneron pays a 0.97x discount to market median. Their most common deal structure is Acquisition, with an average disclosed value of $3.3B. Most recent activity: 2026.
Pipeline coverage & gaps
Sanofi/Regeneron has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 2 | — | $5.6B |
| CollaborationPrimary | 2 | $130M | $2.1B |
| OptionPrimary | 2 | — | $3.6B |
| License | 1 | — | $500M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | Dynavax adjuvant and vaccine portfolio | Dynavax Technologies | vaccines / immunology | unknown | — | $2.2B |
| 2026 | Blueprint Medicines portfolio | Blueprint Medicines | — | unknown | — | $9.0B |
| 2026 | NanoDisc platform | Evoq Therapeutics | autoimmune disorders (celiac disease, Type 1 diabetes, MOG antibody disease, rheumatoid arthritis, lupus) | preclinical | — | $500M |
| 2025 | Deep B-cell depletion platform (DR-0201 and additional candidates) | Dren Bio | autoimmune diseases (B-cell depletion) | unknown | $100M | $1.7B |
| 2025 | AI platform and pipeline expansion (including HXN-1001) | Earendil | ulcerative colitis and Crohn's disease | phase_2 | $160M | $2.6B |
| 2024 | TYK2 programs | Recludix | immunology | preclinical | — | $1.3B |
| 2022 | IgM antibody platform programs | IGM Biosciences | oncology and immunology | discovery | — | $6.0B |
How this is computed
For each Sanofi/Regeneron deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.971, clamped to [0.7, 1.5].